InspireMD Appoints Dan Dearen to Board of Directors

InspireMD ( (NSPR) ) has issued an update.

On September 17, 2025, InspireMD announced the appointment of Dan Dearen to its Board of Directors. With nearly 40 years of experience in the medical device and life sciences sectors, Dearen is expected to bring valuable financial expertise and strategic insight to the company. His appointment comes at a pivotal time as InspireMD continues the U.S. commercial launch of its CGuard Prime stent system, which has received FDA approval. This strategic move is anticipated to enhance InspireMD’s market position and support its growth ambitions in the carotid intervention market.

The most recent analyst rating on (NSPR) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on InspireMD stock, see the NSPR Stock Forecast page.

Spark’s Take on NSPR Stock

According to Spark, TipRanks’ AI Analyst, NSPR is a Neutral.

InspireMD’s overall score reflects a mix of positive developments and ongoing challenges. The FDA approval and strong market reception for CGuard Prime are significant positives, but financial performance issues, including profitability and cash flow challenges, weigh heavily on the score. Technical indicators and valuation metrics also suggest caution.

To see Spark’s full report on NSPR stock, click here.

More about InspireMD

InspireMD, Inc. is a company focused on developing the CGuard® Prime carotid stent system, aimed at preventing strokes. The company seeks to establish its proprietary MicroNet™ mesh technology as the industry standard for carotid stenting, delivering acute results and long-term stroke-free outcomes. InspireMD is publicly traded on Nasdaq under the ticker symbol NSPR.

Average Trading Volume: 182,338

Technical Sentiment Signal: Strong Sell

Current Market Cap: $99.3M

Find detailed analytics on NSPR stock on TipRanks’ Stock Analysis page.